For research use only. Not for therapeutic Use.
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors[1].
Abciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin[2].
Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2].
Abciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia[2].
| Catalog Number | M090905 |
| CAS Number | 143653-53-6 |
| Purity | ≥95% |
| Reference | [1]. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63. [2]. Wu CH, et al. Mechanisms involved in the inhibition of neointimal hyperplasia by abciximab in a rat model of balloon angioplasty. Thromb Res. 2001 Feb 1;101(3):127-38. |
